- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Arformoterol, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 841 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 73
- States / cities
- Birmingham, Alabama • Brimingham, Alabama • Jasper, Alabama + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 6,882
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bacterial Infections
- Interventions
- Cefiderocol/Xeruborbactam
- Drug
- Lead sponsor
- Qpex Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Alzheimer s Disease
- Interventions
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose, Anti-AAV9 Total Antibody (TAb) Assay
- Drug · Device
- Lead sponsor
- Voyager Therapeutics
- Industry
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 2
- States / cities
- Maitland, Florida • Orlando, Florida
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Levomilnacipran, Fluoxetine
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 48
- States / cities
- Dothan, Alabama • Tucson, Arizona • Anaheim, California + 40 more
- Conditions
- Presbyopia
- Interventions
- Lehfilcon A multifocal contact lenses, Lotrafilcon B multifocal contact lenses, CLEAR CARE®
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 8
- States / cities
- Maitland, Florida • Orlando, Florida • Pittsburg, Kansas + 5 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Placebo, JNJ-31001074
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 21
- States / cities
- Irvine, California • Lafayette, California • San Francisco, California + 18 more
- Conditions
- Neoplasms, Breast
- Interventions
- Lapatinib, Trastuzumab
- Drug · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 87
- States / cities
- Phoenix, Arizona • Sedona, Arizona • Highland, California + 79 more
- Conditions
- Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma
- Interventions
- Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study, Sargramostim
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 29 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 91 more
- Conditions
- Stress
- Interventions
- Corporate Athlete® Resilience
- Behavioral
- Lead sponsor
- Johnson & Johnson Health and Wellness Solutions, Inc.
- Industry
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Large B-cell Lymphoma, Follicular Lymphoma
- Interventions
- Axicabtagene Ciloleucel
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 39 more
- Conditions
- Visual Acuity
- Interventions
- soft contact lens in senofilcon A (C3) with HEVL-blocking chromophore, ACUVUE OASYS 1-Day for Astigmatism
- Device
- Lead sponsor
- Johnson & Johnson Vision Care, Inc.
- Industry
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 10
- States / cities
- Jacksonville, Florida • Longwood, Florida • Maitland, Florida + 6 more
- Conditions
- Tourette Syndrome
- Interventions
- Valbenazine, Placebo oral capsule
- Drug
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 34
- States / cities
- Sun City, Arizona • Rogers, Arkansas • Anaheim, California + 27 more
- Conditions
- Leukemia, Pediatric
- Interventions
- Dasatinib
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 88
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 77 more
- Conditions
- HIV Infections
- Interventions
- GSK3640254, Placebo matching GSK3640254 Mesylate salt
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 2
- States / cities
- Bakersfield, California • Orlando, Florida
- Conditions
- Crying
- Interventions
- Milk based infant formula with probiotic, Milk based infant formula
- Other
- Lead sponsor
- Société des Produits Nestlé (SPN)
- Industry
- Eligibility
- 3 Weeks to 4 Months
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2013
- U.S. locations
- 9
- States / cities
- Bentonville, Arkansas • San Francisco, California • Washington D.C., District of Columbia + 6 more
- Conditions
- Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
- Interventions
- Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
- Drug · Procedure · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 390
- States / cities
- Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 290 more
- Conditions
- Major Depressive Disorder
- Interventions
- AXS-05, Bupropion
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 40
- States / cities
- Bellflower, California • Lafayette, California • Oceanside, California + 34 more
- Conditions
- Aortic Valve Disease, Mitral Valve Disease, Endocarditis
- Interventions
- Artificial Mechanical Heart Valve
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- Not listed
- Enrollment
- 807 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2014
- U.S. locations
- 7
- States / cities
- Orlando, Florida • Boston, Massachusetts • Rochester, Minnesota + 3 more
- Conditions
- Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
- Interventions
- Auto-CD34+ cells, Placebo: Diluent used to suspend Auto-CD34+ cells, Standard of care
- Biological · Other
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 291 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 38 more
- Conditions
- Pathological Processes in the Posterior Fossa, Dura Defects
- Interventions
- Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr), Standard of care
- Biological · Procedure
- Lead sponsor
- Baxter Healthcare Corporation
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 12
- States / cities
- Duarte, California • Sacramento, California • San Diego, California + 9 more
- Conditions
- Proteinuric Kidney Disease
- Interventions
- VX-147, Placebo
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 10 Years to 65 Years
- Enrollment
- 522 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 223
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Fairhope, Alabama + 144 more
- Conditions
- Advanced Cancer, Metastatic Cancer, Breast Cancer
- Interventions
- ART4215, Talazoparib, Niraparib
- Drug
- Lead sponsor
- Artios Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more
- Conditions
- Post-ERCP Pancreatitis
- Interventions
- Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement, Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement
- Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,950 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Denver, Colorado • Orlando, Florida + 15 more
- Conditions
- Hepatic Impairment
- Interventions
- GBT440
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida